The FDA has approved Bristol Myers Squibb's novel schizophrenia drug Cobenfy, offering a new treatment option by targeting cholinergic receptors instead of dopamine receptors. Clinical trials show effectiveness in relieving symptoms with fewer side effects, though warnings about potential adverse effects are included.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing